Aspira Women's Health (NASDAQ: AWHL) director reports 135,592-share option grant

Rhea-AI Filing Summary

Aspira Women's Health Inc. director reports new stock option grant. A director of Aspira Women's Health Inc. received a stock option on 12/02/2025 covering 135,592 shares of common stock. The option has an exercise price of $0.35 per share, is listed as exercisable on 12/02/2025, and expires on 12/02/2035. After this transaction, the director beneficially owns 135,592 derivative securities, held directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Wood Jane Pine

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	135,592	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 135,592 shares (Direct)

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 12/03/2025 - 09:33 PM Learn about SEC filing dates

FAQ

What insider transaction was reported for Aspira Women's Health Inc. (AWHL)?

A director of Aspira Women's Health Inc. reported receiving a stock option on 12/02/2025 covering 135,592 shares of common stock.

What is the exercise price of the new stock option reported by the AWHL director?

The stock option reported by the director has an exercise price of $0.35 per share for Aspira Women's Health Inc. common stock.

How many shares underlie the director’s stock option at Aspira Women's Health (AWHL)?

The option is a Stock Option (Right to Buy) covering 135,592 shares of Aspira Women's Health Inc. common stock.

When do the reported AWHL stock options become exercisable and when do they expire?

The reported stock option is shown as exercisable on 12/02/2025 and has an expiration date of 12/02/2035.

How many derivative securities does the Aspira Women's Health director own after this transaction?

Following the reported transaction, the director beneficially owns 135,592 derivative securities, held in direct ownership.

Is the reporting person a director or officer of Aspira Women's Health Inc. (AWHL)?

The reporting person is identified as a Director of Aspira Women's Health Inc. on the form.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wood Jane Pine

(Last) (First) (Middle)

C/O ASPIRA WOMEN'S HEALTH INC

12117 BEE CAVES RD, BLDG 3-100

(Street)

AUSTIN, TX 78738

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Aspira Women's Health Inc. [ AWHL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.35	12/02/2025		A		135,592		12/02/2025	12/02/2035	Common Stock	135,592	$0	135,592	D

Explanation of Responses:

	/s/ Jane Pine Wood	12/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.